Table 4.
| Table 4A. Median effective dose (ED50) for the sequential allocation (SA) study | ||||
|---|---|---|---|---|
| Analysis | Group A (n = 25) | Group G (n = 19) | ED50 ratio (A:G) | p-Value |
| Up-down analysis | 26.8 (22.7–30.9) | 17.7 (13.4–21.9) | 1.51 (1.18–2.01) | 0.009 |
| Probit regression | 27.5 (24.7–30.3) | 17.3 (14.3–20.3) | 1.59 (1.30–1.98) | 0.009 |
| Table 4B. Median effective dose (ED50) for random allocation (RA) study using probit analysis | |||
|---|---|---|---|
| ED50 (95% CI) μg | Group A (n = 77) | Group G (n = 20) | All subjects (n = 97) |
| Spontaneous labor (n = 52) | 29.1 (22.3–35.9) | 15.8 (4.7–26.9) | 27.4 (20.7–34.2) |
| Induced labor (n = 45) | 24.3 (17.8–30.9) | 10.4 (1.7–19.2) | 21.8 (14.8–28.8) |
| All subjects | 27.4 (22.5–32.2) | 12.8 (5.5–20.0) | 25.4 (19.6–31.1) |
Results are ED50 (μg) or ratio with 95% confidence interval.
Group A: 304A homozygotes.
Group G: 304A/G heterozygotes (n = 17) and 304G homozygotes (n = 2).
ED50 ratio (A:G) for genotype is 2.14 (95% CI 1.305.17), p = 0.002.
ED50 ratio (spontaneous:induced) for labor onset is 1.26 (95% CI 0.841.97), p = 0.23.
Tests for goodness of fit and parallelism were p = 0.53 and p = 0.16, respectively.
Group A: 304A homozygotes.
Group G: 304A/G heterozygotes (n = 16) and 304G homozygotes (n = 4).